ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was the target of some unusual options trading on Tuesday. Stock traders purchased 4,022 put options on the stock. This represents an increase of Infinity compared to the average daily volume of 0 put options.

A number of analysts have recently weighed in on the company. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Wednesday. ValuEngine downgraded ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, November 8th. Cowen and Company reiterated a “buy” rating and set a $46.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, November 7th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $47.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the stock. ACADIA Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $47.44.

ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at $27.86 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $24.31 and a fifty-two week high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The company had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. During the same quarter in the previous year, the firm earned ($0.61) EPS. ACADIA Pharmaceuticals’s revenue was up 571.3% on a year-over-year basis. analysts predict that ACADIA Pharmaceuticals will post -2.42 EPS for the current year.

In related news, EVP Glenn Baity sold 37,500 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.25% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of ACAD. Teachers Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 2.2% in the 1st quarter. Teachers Advisors LLC now owns 125,022 shares of the biopharmaceutical company’s stock worth $4,298,000 after purchasing an additional 2,722 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in ACADIA Pharmaceuticals by 138.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 2,548 shares in the last quarter. Legal & General Group Plc increased its holdings in ACADIA Pharmaceuticals by 173.5% in the 1st quarter. Legal & General Group Plc now owns 32,968 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 20,916 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in ACADIA Pharmaceuticals by 2,500.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 198,620 shares of the biopharmaceutical company’s stock worth $6,828,000 after purchasing an additional 190,981 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in ACADIA Pharmaceuticals by 5,422.8% in the 1st quarter. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company’s stock worth $186,791,000 after purchasing an additional 5,334,832 shares in the last quarter. 95.27% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/19/acadia-pharmaceuticals-target-of-unusually-large-options-trading-acad.html.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.